title: Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma.
abstract: Although inhaled corticosteroid (ICS) use is associated with a decreased risk of hospitalization for asthma, the impact of ICS on the risk of life-threatening asthma exacerbation is less clear. The effect of ICS and inhaled beta agonist (IBA) dispensing on the risk of intensive care unit admission for asthma, a surrogate for life-threatening exacerbation, is evaluated. Using computerized International classification of diseases (ICD)-9 discharge diagnoses, a cohort of all 2,344 adult Northern California members of a health maintenance organization hospitalized for asthma over a 2-yr period were identified. Computerized pharmacy data was used to ascertain asthma medications dispensed during the 3-,6-, and 12-month intervals preceding index hospitalization for asthma. During the 3-months preceding hospitalization, a minority of subjects had no IBA units dispensed (34%), with 14% receiving low level (1 unit), 20% medium level (2-3 units), and 32% high level (> or = 4 units) therapy. A substantial proportion received no ICS units (55%), whereas 13% had low, 16% medium, and 15% high level therapy. In multiple logistic regression analysis, high level IBA use was associated with a greater risk of intensive care unit (ICU) admission for asthma after controlling for asthma severity. There was no relationship, however, between low or medium level IBA use and ICU admission. Conversely, medium level and high level ICS use were associated with a reduced risk of ICU admission. Analysing 6- and 12-month medication dispensing data, similar risk patterns were observed. Inhaled corticosteroid dispensing was associated with reduced risk of intensive care unit admission among adults hospitalized for asthma, whereas the opposite applied for high dose beta agonist usage. This suggests that ICS prescription to adults with moderate-to-severe asthma could reduce the risk of life-threatening exacerbation.
authors.affiliation: Cardiovascular Research Institute, Division of Research Northern California Kaiser Permanente, University of California, San Francisco, USA.
authors.forename: M D
authors.initials: MD
authors.lastname: Eisner
authors.forename: T A
authors.initials: TA
authors.lastname: Lieu
authors.forename: F
authors.initials: F
authors.lastname: Chi
authors.forename: A M
authors.initials: AM
authors.lastname: Capra
authors.forename: G R
authors.initials: GR
authors.lastname: Mendoza
authors.forename: J V
authors.initials: JV
authors.lastname: Selby
authors.forename: P D
authors.initials: PD
authors.lastname: Blanc
mesh_terms: D000280:Administration, Inhalation; D000284:Administration, Oral; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D015331:Cohort Studies; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects*; D006760:Hospitalization; D006801:Humans; D007362:Intensive Care Units; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010343:Patient Admission; D012189:Retrospective Studies; D012307:Risk Factors; D000068299:Salmeterol Xinafoate
chemical_list: D000318:Adrenergic beta-Agonists; D005938:Glucocorticoids; D000068299:Salmeterol Xinafoate; D000420:Albuterol